Vertex receives European CHMP positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for CF
Vertex Pharmaceuticals announced that the EMA Committee for Medicinal Products for Human Use adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for treatment of people with cystic fibrosis aged 2 to 5 years old who have two copies of the F508del mutation. November 16, 2018